Immune booster: NK cells join standard care for advanced cancers
NCT ID NCT07551778
First seen May 19, 2026 · Last updated May 20, 2026 · Updated 1 time
Summary
This early-phase study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced solid tumors, including non-small cell lung cancer and colorectal cancer. About 20 adults aged 18-75 will receive NK cell infusions alongside their usual drugs. The main goals are to check safety and see if the combination slows cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.